Initial supplementary dose of dolutegravir in second-line antiretroviral therapy: a non-comparative, double-blind, randomised placebo-controlled trial.
Ying ZhaoRulan GrieselZaayid OmarBryony SimmonsAndrew HillGert U van ZylClaire KeeneGary MaartensGraeme MeintjesPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
Our findings do not support the need for initial dolutegravir dose adjustment in patients switching to TLD who failed first-line TEE.
Keyphrases
- antiretroviral therapy
- double blind
- hiv infected patients
- clinical trial
- hiv infected
- placebo controlled
- end stage renal disease
- human immunodeficiency virus
- study protocol
- ejection fraction
- hiv aids
- newly diagnosed
- hiv positive
- open label
- peritoneal dialysis
- randomized controlled trial
- phase iii
- phase ii
- hepatitis c virus
- men who have sex with men